For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...
HealthDay on MSN2d
Talazoparib + Enzalutamide Tied to Improved Overall Survival in Metastatic Prostate CancerFor patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination r ...
Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic ...
Darolutamide may offer greater benefits than enzalutamide or apalutamide for Black and White patients with non-metastatic ...
Talazoparib plus enzalutamide boosts overall survival in metastatic castration-resistant prostate cancer, with HRR-deficient ...
in metastatic castration-sensitive prostate cancer (mCSPC). Pharmacokinetic parameters edoxaban with and without enzalutamide (data are represented as geometric mean (CV%) [confidence interval]).
Treatment (Rx) patterns and attrition rates in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Real world comparison of time-to-next-treatment (TTNT), ...
Adding stereotactic body radiotherapy to enzalutamide and ADT for oligometastatic castration-resistant prostate cancer prolongs radiographic progression-free survival. Adding metastasis-directed ...
Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback